---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-310469"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T14:02:37.710712+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma reports 93% ORR in 3L+ LBCL for ronde-cel at ASH

## Summary
- In 3L+ setting (n=29 evaluable): 93% ORR, 76% CR; median PFS 18 months at 12-month median follow-up.
- In 2L setting (n=18 evaluable, 94% primary refractory): 83% ORR, 61% CR; median duration of CR not reached.
- Safety (n=69): no Grade ≥3 CRS; one Grade ≥3 ICANS case (4% with dex prophylaxis); no treatment-related deaths.
- Ronde-cel showed up to 3-fold higher expansion vs approved CD19 CAR-T products and higher memory-cell phenotype.
- Data cutoff Sep 5, 2025; ronde-cel is dual-targeting CD19/CD20 CAR-T with CD62L enrichment manufacturing.

## SEC filing metadata
- accession: 0001193125-25-310469
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312525310469/0001193125-25-310469-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312525310469/d35459d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-310469
- JSON: https://secwatch.observer/filing/0001193125-25-310469.json
- Plain text: https://secwatch.observer/filing/0001193125-25-310469.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.